Crónicas de un exiliado huertista en La Habana

Capítulos de libr

Pensar en México desde La Habana : los exiliados huertistas en Cuba

Capítulos de libr

Los exiliados huertistas contra la Constitución de 1917

En el presente capítulo la autora da a conocer como el exilio generado por la Revolución mexicana fue diverso, pues, a lo largo de todos los años de lucha hubo oleadas de personas de diversas corrientes de pensamiento y filiaciones políticas que se vieron obligadas a salir del país ante el triunfo o la imposición de sus adversarios políticos.Trabajo realizado con el apoyo del Programa UNAM DGAPA-PAPIIT IN30302

México y Cuba : perspectivas históricas y culturales de la relación bilateral

Entre México y Cuba históricamente han existido múltiples vinculaciones estimuladas tanto por su proximidad geográfica como por su identidad cultural y su herencia colonial compartida. Sobre esas temáticas versan los textos que componen este libro, que van desde los ámbitos musical, dancístico y estético, que generaron circuitos de influencias e intercambios a lo largo del siglo XX, pasando por el exilio de mexicanos en la Isla, los movimientos revolucionarios experimentados por ambos países en momentos históricos particulares y la consecuente evolución de la relación bilateral, hasta llegar a su recomposición en las primeras décadas del siglo XXI. El dinamismo de los vínculos mexicano-cubanos, cuya impronta se refleja en el ámbito regional e internacional, suscita siempre el interés por su estudio y análisis.Libro

Exilio Iberoamericano

Universidad Nacional Autónoma de México/Programa de Apoyo a Proyectos de Investigación e Innovación/"PAPIIT IG400117"//[Dinámica de los exilios en Iberoamérica]Exilio iberoamericano es parte de los estudios sobre este tema en los siglos XIX y XX. Los ensayos que componen la obra, realizados por investigadores de diversas nacionalidades y disciplinas, muestran la movilidad forzada de ciertos sectores de la población de diferentes países. Su aporte central radica en mirar esos desplazamientos a través de las coyunturas políticas que han afectado a distintas naciones en los ámbitos regional y mundial, y que motivaron el exilio de grupos de activistas políticos, intelectuales y científicos, así? como la salida masiva de ciudadanos en busca de salvaguardar su vida. Un texto imprescindible para comprender las causas y efectos de este fenómeno, así? como para evitar su repetición en el siglo XXI.Libro

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols

Clinical and genetic characteristics of late-onset Huntington's disease

Background: The frequency of late-onset Huntington's disease (>59 years) is assumed to be low and the clinical course milder. However, previous literature on late-onset disease is scarce and inconclusive. Objective: Our aim is to study clinical characteristics of late-onset compared to common-onset HD patients in a large cohort of HD patients from the Registry database. Methods: Participants with late- and common-onset (30–50 years)were compared for first clinical symptoms, disease progression, CAG repeat size and family history. Participants with a missing CAG repeat size, a repeat size of ≤35 or a UHDRS motor score of ≤5 were excluded. Results: Of 6007 eligible participants, 687 had late-onset (11.4%) and 3216 (53.5%) common-onset HD. Late-onset (n = 577) had significantly more gait and balance problems as first symptom compared to common-onset (n = 2408) (P <.001). Overall motor and cognitive performance (P <.001) were worse, however only disease motor progression was slower (coefficient, −0.58; SE 0.16; P <.001) compared to the common-onset group. Repeat size was significantly lower in the late-onset (n = 40.8; SD 1.6) compared to common-onset (n = 44.4; SD 2.8) (P <.001). Fewer late-onset patients (n = 451) had a positive family history compared to common-onset (n = 2940) (P <.001). Conclusions: Late-onset patients present more frequently with gait and balance problems as first symptom, and disease progression is not milder compared to common-onset HD patients apart from motor progression. The family history is likely to be negative, which might make diagnosing HD more difficult in this population. However, the balance and gait problems might be helpful in diagnosing HD in elderly patients